Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis Market Insights and Opportunities, 2021- Market Size, Share, Trends by Drug Type (Pirfenidone, Nintedanib, Generic Pirfenidone, Pamrevlumab), Mechanism of Action (Anti-Fibrotic Agent, Tyrosine kinase inhibitor, CGTF inhibitor), Others

  • Home
  • Healthcare
  • Idiopathic Pulmonary Fibrosis Market
  • |Published Month : January, 2023
  • |No. of Pages : 135

Idiopathic Pulmonary Fibrosis Market Size stood at USD 2.88 billion in 2020 and over the forecast period, the market will register 4.01% CAGR. The market shares across drug types including Pirfenidone, Nintedanib, Generic Pirfenidone, Pamrevlumab, mechanism of action including Anti-Fibrotic Agent, Tyrosine kinase inhibitor, CGTF inhibitor and others.


Idiopathic Pulmonary Fibrosis Market Report Highlights-

  • The global Idiopathic Pulmonary Fibrosis market size is estimated to reach $3.94 Billion in 2028 from $2.88 Billion in 2020, at a CAGR of 4.01% between 2020 and 2028.
  • The demand for Idiopathic Pulmonary Fibrosis from emerging Asian and Latin American countries is poised to increasing rapidly, in particular, from second half of forecast period, following the launch of generics.
  • Increasing prevalence of the condition and growing awareness and affordability driven by launch of generics and strong pipeline to reverse the disease are poised to drive the market.
  • Idiopathic Pulmonary Fibrosis (IPF) is a rare disease with an estimated prevalence in Europe and North America of 3–9 cases per 100,000.
  • Median survival without therapy is 2–3 years
  • Over 200,000 patients suffer from IPF in the US and Europe. Accordingly, IPF is considered a rare disease

Approved Drugs for Idiopathic Pulmonary Fibrosis- Esbriet (Roche) and Ofev (Boehringer Ingelheim)

Pipeline Candidates for Idiopathic Pulmonary Fibrosis- Phase 3 (Ziritaxestat, Pamrevlumab); Phase 2 (PRM-151, GB0139, Fezagepras, CC-90001)

Developments likely to impact the industry

  • Patent expiry of Esbriet in October 2021
  • Ziritaxestat trial discontinued
  • Launch of Pamrevlumab
  • Generics entry into the industry and negative impact on growth of Ofev and Esbriet


Idiopathic Pulmonary Fibrosis Market Size Outlook

IDIOPATHIC PULMONARY FIBROSIS Market Size Outlook- 2020 2021 2022 2023 2024 2025 2026 2027 2028

Idiopathic Pulmonary Fibrosis Market Analysis, 2021

Growing awareness about Idiotic pulmonary fibrosis (IPF), increasing prevalence of the condition, ageing and changing lifestyles coupled with smoking habits and absence of reversal treatment for IPF are encouraging companies to invest significantly in R&D to gain from the huge unmet demand. Companies like Gilead Sciences, Fibrogen, Promedior, Galecto, Liminal BioSciences, Celgene Corp and others are focusing on constantly assessing diverse mechanism of actions to identify potential treatment options.


IPF is a progressive, irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis, or scarring, in the lungs. The condition causes shortness of breath, and a deterioration in lung function and exercise tolerance. The median survival time from diagnosis is two to three years. It typically occurs in patients over the age of 45, and tends to affect slightly more men than women. IPF is associated with increasing cough and dyspnea, greatly impacting patient quality of life and eventually leading to death from respiratory failure or complicating comorbidities.


The global Idiopathic Pulmonary Fibrosis market is valued at $2,878 million in 2020. Further, over the forecast period to 2028, the market is poised to register 4.01% growth (Compounded Annual Growth Rate- CAGR) to reach $3,942 million in 2028. The major factors shaping up the demand outlook include increasing incidences of disease, expiry of Esbriet patent, launch of generics, and possible approval of Pamrevlumab. On the other hand, low penetration rate in developing markets, low awareness and affordability in these markets, unknown etiology of the condition, and inadequate and difficult diagnosis are main market challenges.


The report analyses the global Idiopathic Pulmonary Fibrosis market across drug types, mechanism of actions and geographies. The drug types analysed in the report include Pirfenidone, Nintedanib, Generic Pirfenidone and Pamrevlumab. Among types, Nintedanib remain the dominant drug type with 54.5% market share.

IDIOPATHIC PULMONARY FIBROSIS Market Outlook- Anti-Fibrotic Agent, Tyrosine Kinase Inhibitor

In terms of mechanism of action, the market is categorized into Anti-Fibrotic Agents, Tyrosine kinase inhibitor, and CGTF inhibitor. Of these Tyrosine kinase inhibitor dominated the industry in terms of market size with 54.6% market share.


High awareness and affordability coupled with increasing prevalence of the disease are the main market drivers for Idiopathic Pulmonary Fibrosis in developed countries in North America, and Europe. Among regions, North America remained the global markets with the US being the world’s largest country for IPF treatment. The region accounted for 70.9% of global market demand, followed by Europe (21%). On the other hand, Asia Pacific is the fastest growing geography, forecast to register 7.99% CAGR over the forecast period. The fastest growth in China, India, South Korea, Brazil, Russia and other countries is driven by launch of generics and availability of Pamrevlumab in the second half of forecast period.


In terms of companies, the current market landscape is characterized by presence of only two companies- Boehringer Ingelheim and F. Hoffman La Roche.


Idiopathic Pulmonary Fibrosis Market Trends- Small companies offer potential investment and partnership opportunities


Small and medium size companies developing late stage pipeline therapeutic candidates for IPF seek out potential investors, federal funding, or strategic partnering with larger and mature companies in the form of licensee or through strategic alliances.


Esbriet was originally developed by InterMune (a Brisbane, California based biotechnology company) and it reached definitive merger agreement with Roche in August 2014.


Similarly, in February 2020, Promedior, Inc (developing PRM 151) announced the successful completion of its previously announced sale to Roche


Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases have merged into single company- Galecto. The emerging company continues to focus on TD139/ GB0139.


Idiopathic Pulmonary Fibrosis Market Drivers- Idiopathic Pulmonary Fibrosis (IPF) has Strong Unmet Demand


IPF presents significant unmet demand potential. As both the approved drugs do not improve fatal prognosis of IPF but instead slows the progression, there exists huge unmet market demand.


Further, high rate of treatment discontinuation and also presents side effects such as gastrointestinal side effects, liver problems, nausea and vomiting, diarrhea, weight loss, high blood pressure and others.


Companies often use six-minute walking test (6 MWT) as one of the standard tests to obtain acceptance by physicians and patients. Pharmaceutical companies and institutes are investing in developing a drug that has minimal side effects and has more efficacy.


FibroGen Inc. Idiopathic Pulmonary Fibrosis Market Company Analysis

Based in San Francisco, FibroGen, Inc. is a world-class leading research-based biopharmaceutical company that engages in the discovery, development, and commercialization of the pipeline of first-in-class novel therapeutics.

The company is currently focused on developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development. It is used for the treatment of anemia in chronic kidney disease;

FibroGen is also developing FG-3019, a monoclonal antibody that is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage.


Key R&D product pipeline:

  • Roxadustat
  • Pamrevlumab


Roxadustat is also in clinical trials and is an oral small molecule inhibitor of HIF prolyl hydroxylase (“HIF-PH”) activity that has received New Drug Application (“NDA”) approval in anemia associated with chronic kidney disease (“CKD”) in dialysis-dependent (“DD”) patients from the National Medical Products Administration (“NMPA”) (previously known as the China Food and Drug Administration) of the People’s Republic of China (“China”).

Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

The company was founded in 1993 and is headquartered in San Francisco, CA.

1.1 List of Tables
1.2 List of Figures    7

2.1 Summary    9
2.1.1 Overview    9
2.1.2 Market Sales    10
2.1.3 Approved Drugs    10
2.1.4 Pipeline Candidates    11
2.1.5 Developments likely to impact the industry    11
2.2 Idiopathic Pulmonary Fibrosis Industry Outlook, 2020 – 2028    12
2.3 Abbreviations    13

3.1 Market Segments - Types, Applications, and Countries    14
3.2 Report Guide    15
3.3 Research Methodology    16

4.1 GDP Outlook, 2020 – 2030    17
4.2 Population Outlook of Select Countries, 2020 – 2030    18

5.1 Industry Panorama    19
5.2 Major Companies    21
5.3 Market Trends    21
5.3.1 Small companies offer potential investment and partnership opportunities    22
5.3.2 IPF has Strong Unmet Demand    22
5.3.3 Companies assessing diverse mechanism of actions    23
5.3.4 Special status for pipeline candidates    23
5.3.5 Unknown etiology poses challenges for new product development    23
5.3.6 Inadequate and difficult diagnosis challenges prevalence estimation in developing countries    25
5.3.7 Increasing global Healthcare Expenditure worldwide is among the main market drivers    26

5.4 Leading Drug Types    27
5.4.1 Pirfenidone (Esbriet)    28
5.4.2 Nintedanib (Ofev)    30
5.4.3 Others    31

5.5 Dominant Mechanism of Action    34
5.5.1 Anti-Fibrotic Agents    35
5.5.2 Tyrosine kinase inhibitor    36
5.5.3 Others    37

5.6 Regional Outlook    38

6.1 Post COVID Scenario    40
6.2 Pre COVID Scenario    41

7.1 Overview    42
7.1.1 The US dominates the North American Idiopathic Pulmonary Fibrosis Market    43
7.3 Market Outlook by Country    44

7.3.1 The US    44
7.3.2 Other North America    45

8.1 Overview    46
8.1.1 Germany dominates the European Idiopathic Pulmonary Fibrosis Market    47
8.2 Market Outlook by Country    48
8.2.1 Germany    48
8.2.2 United Kingdom    49
8.2.3 France    50
8.2.4 Spain    51
8.2.5 Italy    52
8.2.6 Other Europe    53

9.1 Overview    54
9.1.1 China dominates the Asia Pacific Idiopathic Pulmonary Fibrosis Market    55
9.2 Market Outlook by Country    56
9.2.1 Japan    56
9.2.2 Other Asia Pacific    57

10.1 Overview    58

11.1 Boehringer Ingelheim GmbH    59
11.1.1 Overview    59
11.1.2 SWOT Analysis    62
11.2 FibroGen Inc    65
11.2.1 Overview    65
11.2.2 SWOT Analysis    66
11.2.3 Key Financials    69
11.3 Liminal Biosciences Inc    72
11.3.1 Overview    72
11.3.2 SWOT Analysis    74
11.3.3 Key Financials    76
11.4 Medicinova Inc    79
11.4.1 Overview    79
11.4.2 SWOT Analysis    81
11.4.3 Key Financials    83
11.5 F. Hoffmann-LA Roche    86
11.5.1 Overview    86
11.5.2 SWOT Analysis    88
11.5.3 Key Financials    90

12.1 Stem Cell Study into Repairing Damaged Lungs Wins $100K ALA Grant    93
12.2 Gilead's $5B Galapagos black hole widens as pair tosses out phase 3 asset after flop    95
12.3 Paragonix Announces First-in-Man use of LUNGguard Donor Lung Preservation System by Duke Hospital    97
12.4 Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial    99
12.5 Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis    100
12.6 First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis    101
12.7 Targeted therapies developed to reduce lung fibrosis    102
12.8 Genkyotex Announces the Enrollment of the 1st Patient in the Phase 2 Trial of Setanaxib in Idiopathic Pulmonary Fibrosis (IPF)    103

13.    APPENDIX    105
13.1 About USD Analytics    105
13.2 Sources and Research Methodology    105
13.3 Copyright and Disclaimer    106

Sample Request